Montgomery William, Treuer Tamas, Karagianis Jamie, Ascher-Svanum Haya, Harrison Gavan
Global Health Outcomes, Eli Lilly and Company, Sydney, Australia.
Patient Prefer Adherence. 2012;6:109-25. doi: 10.2147/PPA.S27344. Epub 2012 Feb 1.
Orally disintegrating olanzapine (ODO) is a rapid-dissolving formulation of olanzapine which disintegrates in saliva almost immediately, developed as a convenient and adherence-enhancing alternative to the standard olanzapine-coated tablet (SOT). Clinical studies, which form the basis of this review, have shown ODO and SOT to have similar efficacy and tolerability profiles. However, ODO appears to have a number of advantages over SOT in terms of adherence, patient preference, and reduction in nursing burden. Overall, the existing clinical data suggests that compared to SOT, ODO is not only well-suited for difficult-to-treat, agitated, and/or nonadherent patients but, due to its potential ability to improve adherence and greater patient preference, may also be an appropriate formulation for the majority of patients for which olanzapine is the antipsychotic of choice.
口腔崩解型奥氮平（ODO）是奥氮平的一种速溶制剂，几乎能立即在唾液中崩解，它是作为标准奥氮平包衣片（SOT）的一种方便且能提高依从性的替代剂型而开发的。构成本综述基础的临床研究表明，ODO和SOT具有相似的疗效和耐受性特征。然而，ODO在依从性、患者偏好以及减轻护理负担方面似乎比SOT有许多优势。总体而言，现有临床数据表明，与SOT相比，ODO不仅适用于难治性、躁动和/或不依从的患者，而且由于其潜在的提高依从性的能力和更高的患者偏好性，对于大多数将奥氮平作为首选抗精神病药物的患者来说，也可能是一种合适的剂型。
